Welcome to our dedicated page for Seres Therapeutics news (Ticker: MCRB), a resource for investors and traders seeking the latest updates and insights on Seres Therapeutics stock.
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage live biotherapeutics company that regularly issues news about its microbiome-based drug programs, regulatory interactions, and corporate developments. The company focuses on oral live biotherapeutics for medically vulnerable patient populations, particularly adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) and other high-risk groups.
News about Seres often centers on its lead investigational candidate SER-155, including Phase 1b clinical data showing a significant reduction in bacterial bloodstream infections, systemic antibiotic exposure, and febrile neutropenia in allo-HSCT patients compared with placebo. Updates also cover regulatory designations for SER-155, such as Breakthrough Therapy and Fast Track status, and detailed feedback from the U.S. Food and Drug Administration on the design of a planned Phase 2 study.
Investors and followers of MCRB can expect announcements on clinical trial progress, investigator-sponsored studies in areas like immune checkpoint inhibitor–related enterocolitis, and research presentations at major medical meetings. Seres also issues press releases on mechanistic publications for its live biotherapeutics, including VOWST™, and on data generated from its MbTx® platform that support its broader live biotherapeutic strategy.
In addition to R&D updates, Seres publishes news on cost-reduction actions, cash runway expectations, leadership changes, and efforts to secure capital or partnerships to advance its pipeline. For those tracking MCRB, this news feed provides a centralized view of program milestones, scientific data, regulatory interactions, and corporate actions that shape the company’s live biotherapeutics portfolio.
Seres Therapeutics (Nasdaq: MCRB) reported Q2 2024 financial results and provided business updates. Key highlights include:
1. VOWST asset sale to provide $175M cash infusion, less ~$20M in settlement obligations.
2. SER-155 Phase 1b Cohort 2 clinical readout on track for September.
3. Q2 2024 net loss of $32.9M compared to net income of $46.6M in Q2 2023.
4. VOWST Q2 2024 net sales of $14.4M, up 43% from Q1.
5. Cash runway expected into Q4 2025 post-VOWST sale.
The company plans to focus on developing cultivated live biotherapeutics for medically vulnerable populations at risk of serious bacterial infections.
Seres Therapeutics (Nasdaq: MCRB) has signed an agreement to sell its VOWST business to Nestlé Health Science. Upon closing, Seres will receive a $175M cash infusion, including an upfront payment, prepaid milestone, and equity investment. Additional $75M in payments are due in 2025, with potential future milestone payments of up to $275M based on VOWST sales targets.
Seres will fully retire its debt and expects to fund operations into Q4 2025. The company will focus on developing next-generation cultivated live biotherapeutic candidates for medically vulnerable populations. The lead program, SER-155, is on track for Phase 1b data in September. The deal is expected to close within 90 days, subject to shareholder approval.
Seres Therapeutics (Nasdaq: MCRB), a leading live biotherapeutics company, has announced that it will host a conference call and live audio webcast on August 13, 2024, at 8:30 a.m. ET to discuss its second quarter 2024 financial results and provide business updates. Investors and interested parties can access the conference call by dialing 800-715-9871 (domestic) or 646-307-1963 (international) and referencing the conference ID number 4877586. A live webcast will be available in the 'Investors and News' section of the Seres website, with a replay accessible approximately two hours after the event and archived for about 21 days.
On June 5, 2024, Seres Therapeutics (Nasdaq: MCRB) announced the granting of inducement equity awards to a new employee. The Compensation and Talent Committee allocated 6,188 shares, divided into 4,125 stock options and 2,063 restricted stock units (RSUs). These grants are part of the 2022 Employment Inducement Award Plan, adopted in December 2022, aiming to attract new talent under Nasdaq's Listing Rule 5635(c)(4). The stock options have an exercise price of $1.14 per share and vest incrementally over four years. Similarly, the RSUs vest over a four-year period, with the first vesting date one year from the employee's hire date.
Seres Therapeutics announced that Nestlé Health Science will acquire global rights to VOWST, a microbiota-based therapeutic.
This agreement follows a non-binding memorandum of understanding and will give Nestlé full control over the development, commercialization, and manufacturing of VOWST globally.
VOWST, FDA-approved in June 2023, is the first oral microbiota-based treatment to prevent recurrence of Clostridioides difficile infection (CDI) in adults after antibacterial treatment.
The deal requires negotiation of definitive agreements, Seres shareholder approval, and other customary conditions.
Seres Therapeutics announced a memorandum of understanding with Nestlé Health Science to sell its VOWST assets, which include intellectual property rights. The deal is expected to provide Seres with capital infusions and an upfront payment, allowing the company to retire its debt and extend its cash runway into Q4 2025. The transaction, anticipated to complete within 90 days, is subject to shareholder approval and other conditions. Seres will shift focus to advancing SER-155 and other microbiome therapeutics. This agreement builds on a previous license agreement with Nestlé and recent FDA approval for VOWST to treat recurrent CDI. Seres expects this deal to strengthen its balance sheet and enable progress in its therapeutic programs.
Seres Therapeutics, Inc. (Nasdaq: MCRB) reported first quarter 2024 financial results highlighting net sales of $10.1 million for VOWST, accelerating sales growth since launch, and progress in clinical trials. The company aims to expand its product franchise into additional patient populations and secure more capital for pipeline development.
Seres Therapeutics, Inc. announced the grant of equity awards to two new employees under the Inducement Plan. The grants consist of stock options and RSUs, totaling 9,367 shares of common stock. These awards are subject to specific vesting schedules and were granted under Nasdaq Listing Rule 5635(c)(4).
Seres Therapeutics, Inc. (Nasdaq: MCRB) will discuss their first quarter 2024 financial results and provide business updates on May 8, 2024. The conference call and webcast are scheduled for 8:30 a.m. ET. Investors can access the call by dialing the provided numbers or by visiting the Seres website. A replay will be available on the website for 21 days.
Summary not available.
FAQ
What is the current stock price of Seres Therapeutics (MCRB)?
What is the market cap of Seres Therapeutics (MCRB)?
